CERS

Cerus Corporation

Cerus Corporation is dedicated solely to safeguarding the world\'s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

Cerus Corporation (CERS) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Value (D+). The rating has held at C+ for 10 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
D+
Factor Score 1.7 / 5.0
Growth
B-
Factor Score 3.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 130.0
EV / EBITDA -551.2
Rev Growth YoY 9.5%
Gross Margin 51.8%
Price Return 3M -28.0%
Price Return 12M 14.0%
Catalyst Signal 0.00
Market Cap $393.8M
TTM Revenue $226.6M
Price / Sales 1.7
ROE -10.7%

Historical Factor Score Progression

Held C+ for 10 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 D+ (1.7) B- (3.1) C+ (2.8) C (2.5) C+ (2.6) C+ (2.5)
2026-11-04 D+ (1.5) B- (3.0) C+ (2.8) B- (3.1) C+ (2.7) C+ (2.6)
2026-10-28 D+ (1.5) B- (3.0) C+ (2.8) B- (2.9) C+ (2.7) C+ (2.6)
2026-10-21 D+ (1.5) B- (3.0) C+ (2.8) B- (2.9) C+ (2.6) C+ (2.6)
2026-10-14 D+ (1.5) B- (3.0) C+ (2.8) C+ (2.7) C+ (2.6) C+ (2.5)
Page 1 of 8
…